INMED PHARMACEUTICALS INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
INMED PHARMACEUTICALS INC. (INM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$8.55 million for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was -$1.74M.
- INMED PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was -$988.57K.
- INMED PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-09-30 was -$2.17M, a 168.51% decline year-over-year.
- INMED PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-09-30 was $3.17M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$8.55M S-4/A · filed 2026-09-09 | ||||
| 2026-03-31 | -$5.58M S-4 · filed 2026-07-02 | ||||
| 2025-12-31 | -$4.12M 10-Q · filed 2026-02-11 | ||||
| 2025-09-30 | -$1.74M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $4.17M S-4/A · filed 2026-09-09 | $4.50M 10-K · filed 2025-09-23 | |||
| 2025-03-31 | -$1.89M S-4 · filed 2026-07-02 | ||||
| 2024-12-31 | -$3.15M 10-Q · filed 2026-02-11 | ||||
| 2024-09-30 | -$988.57K 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | -$2.34M S-4 · filed 2026-07-02 | ||||
| 2024-03-31 | -$1.31M 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | $622.40K 10-Q · filed 2025-02-12 | ||||
| 2023-09-30 | -$2.17M 10-Q · filed 2024-11-14 | ||||
| 2022-09-30 | $3.17M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |